• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Platinum-Based Adjuvant Chemotherapy for Stage II and Stage III Squamous Cell Carcinoma of the Lung.铂类辅助化疗用于Ⅱ期和Ⅲ期肺鳞状细胞癌
Ann Thorac Cardiovasc Surg. 2017 Feb 20;23(1):19-25. doi: 10.5761/atcs.oa.16-00164. Epub 2016 Dec 27.
2
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.奈达铂联合多西他赛与顺铂联合多西他赛治疗晚期或复发性肺鳞状细胞癌（WJOG5208L）：一项随机、开放标签、III 期临床试验。
Lancet Oncol. 2015 Dec;16(16):1630-8. doi: 10.1016/S1470-2045(15)00305-8. Epub 2015 Oct 28.
3
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.耐昔妥珠单抗联合吉西他滨和顺铂与吉西他滨和顺铂单药一线治疗局部晚期或转移性鳞状非小细胞肺癌患者（SQUIRE）：一项开放标签、随机、对照的 3 期临床试验。
Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1.
4
Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.紫杉醇联合顺铂新辅助化疗治疗 III 期 N2 非小细胞肺癌。
Clin Lung Cancer. 2013 Jul;14(4):418-24. doi: 10.1016/j.cllc.2012.10.003. Epub 2013 Jan 4.
5
Adjuvant docetaxel and carboplatin chemotherapy administered alone or with radiotherapy in a "sandwich" protocol in patients with advanced endometrial cancer: a single-institution experience.晚期子宫内膜癌患者中采用单独或联合放疗法的“夹心”方案给予辅助多西他赛和卡铂化疗：单机构经验。
Expert Opin Pharmacother. 2013 Apr;14(5):535-42. doi: 10.1517/14656566.2013.778243.
6
Adjuvant chemotherapy may improve prognosis after resection of stage I lung cancer with lymphovascular invasion.辅助化疗可能改善有血管淋巴管侵犯的 I 期肺癌切除术后的预后。
J Thorac Cardiovasc Surg. 2018 Nov;156(5):2006-2015.e2. doi: 10.1016/j.jtcvs.2018.06.034. Epub 2018 Jul 18.
7
Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.在两项 II 期临床试验中，接受培美曲塞治疗的 IIIB/IV 期非小细胞肺癌患者的组织学比较。
Clin Lung Cancer. 2010 Mar 1;11(2):126-31. doi: 10.3816/CLC.2010.n.017.
8
A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.培美曲塞联合顺铂或卡铂作为完全切除的ⅠB期或Ⅱ期非小细胞肺癌患者辅助化疗的随机2期研究。
Lung Cancer. 2015 Dec;90(3):397-404. doi: 10.1016/j.lungcan.2015.11.007. Epub 2015 Nov 7.
9
Platinum-based combination chemotherapy vs. weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis.铂类联合化疗与每周顺铂辅助 CCRT 治疗盆腔淋巴结转移早期宫颈癌的比较。
Anticancer Res. 2013 Oct;33(10):4675-81.
10
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.辅助性紫杉醇加卡铂与ⅠB期非小细胞肺癌观察治疗的比较：癌症和白血病B组、放射治疗肿瘤学组及北中部癌症治疗组研究组的CALGB 9633研究
J Clin Oncol. 2008 Nov 1;26(31):5043-51. doi: 10.1200/JCO.2008.16.4855. Epub 2008 Sep 22.

引用本文的文献

1
Surgical Treatment Outcomes of Patients with Non-Small Cell Lung Cancer and Lymph Node Metastases.非小细胞肺癌伴淋巴结转移患者的外科治疗结果
Cancers (Basel). 2023 Jun 7;15(12):3098. doi: 10.3390/cancers15123098.
2
Adjuvant chemotherapy for completely resected IIA-IIIA non-small cell lung cancer: compliance to guidelines, safety and efficacy in real-life practice.完全切除的IIA-IIIA期非小细胞肺癌的辅助化疗：在现实临床实践中对指南的依从性、安全性和疗效
Transl Lung Cancer Res. 2022 Dec;11(12):2418-2437. doi: 10.21037/tlcr-22-345.
3
Use of adjuvant chemotherapy in resected non-small cell lung cancer in real-life practice: a systematic review of literature.辅助化疗在现实临床实践中用于可切除非小细胞肺癌的情况：一项文献系统综述
Transl Lung Cancer Res. 2021 Dec;10(12):4643-4665. doi: 10.21037/tlcr-21-557.
4
USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma.USP28 缺失和小分子抑制使 c-MYC 不稳定并引发鳞状细胞肺癌消退。
Elife. 2021 Oct 12;10:e71596. doi: 10.7554/eLife.71596.
5
KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma.KIAA1522 增强 TNFα-NFκB 信号通路以拮抗肺腺癌的铂类化疗。
J Exp Clin Cancer Res. 2020 Aug 27;39(1):170. doi: 10.1186/s13046-020-01684-x.
6
LUBAC determines chemotherapy resistance in squamous cell lung cancer.LUBAC 决定鳞状细胞肺癌的化疗耐药性。
J Exp Med. 2019 Feb 4;216(2):450-465. doi: 10.1084/jem.20180742. Epub 2019 Jan 14.

本文引用的文献

1
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.奈达铂联合多西他赛与顺铂联合多西他赛治疗晚期或复发性肺鳞状细胞癌（WJOG5208L）：一项随机、开放标签、III 期临床试验。
Lancet Oncol. 2015 Dec;16(16):1630-8. doi: 10.1016/S1470-2045(15)00305-8. Epub 2015 Oct 28.
2
Comparisons of the clinicopathological features and survival outcomes between lung cancer patients with adenocarcinoma and squamous cell carcinoma.肺腺癌和肺鳞癌患者的临床病理特征及生存结果比较。
Gen Thorac Cardiovasc Surg. 2015 Sep;63(9):507-13. doi: 10.1007/s11748-015-0564-5. Epub 2015 May 30.
3
Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010.1973 - 2010年美国肺癌发病率按性别、种族和组织学类型的变化趋势
PLoS One. 2015 Mar 30;10(3):e0121323. doi: 10.1371/journal.pone.0121323. eCollection 2015.
4
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.重点：培美曲塞维持治疗对比安慰剂用于培美曲塞联合顺铂诱导治疗后晚期非鳞状非小细胞肺癌的 III 期研究的最终总生存结果。
J Clin Oncol. 2013 Aug 10;31(23):2895-902. doi: 10.1200/JCO.2012.47.1102. Epub 2013 Jul 8.
5
Nedaplatin: a cisplatin derivative in cancer chemotherapy.奈达铂：癌症化疗中的顺铂衍生物。
Cancer Manag Res. 2013 May 8;5:67-76. doi: 10.2147/CMAR.S35785. Print 2013.
6
Differences between squamous cell carcinoma and adenocarcinoma of the lung: are adenocarcinoma and squamous cell carcinoma prognostically equal?肺鳞癌与肺腺癌的差异：肺腺癌和肺鳞癌的预后是否相当？
Jpn J Clin Oncol. 2012 Mar;42(3):189-95. doi: 10.1093/jjco/hyr188. Epub 2011 Dec 30.
7
Prognostic impact of histology on early-stage non-small cell lung cancer.组织学对早期非小细胞肺癌的预后影响。
Chest. 2011 Jul;140(1):135-145. doi: 10.1378/chest.10-2391. Epub 2010 Dec 16.
8
Comparison of nedaplatin and irinotecan for patients with squamous and nonsquamous cell carcinoma of the lung: meta-analysis of four trials.比较奈达铂和顺铂治疗非小细胞肺癌的疗效和安全性的 Meta 分析。
J Thorac Oncol. 2011 Jan;6(1):128-31. doi: 10.1097/JTO.0b013e3181ccb3a9.
9
Japanese Lung Cancer Registry Study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002.日本肺癌注册研究：2002 年首次前瞻性纳入大量手术和非手术病例。
J Thorac Oncol. 2010 Sep;5(9):1369-75. doi: 10.1097/JTO.0b013e3181e452b9.
10
Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation.完全切除的非小细胞肺癌的辅助顺铂和长春瑞滨：肺辅助顺铂评估的亚组分析。
J Thorac Oncol. 2010 Feb;5(2):220-8. doi: 10.1097/JTO.0b013e3181c814e7.

铂类辅助化疗用于Ⅱ期和Ⅲ期肺鳞状细胞癌

Platinum-Based Adjuvant Chemotherapy for Stage II and Stage III Squamous Cell Carcinoma of the Lung.

作者信息

Isaka Tetsuya, Nakayama Haruhiko, Yokose Tomoyuki, Ito Hiroyuki, Katayama Kayoko, Yamada Kouzo, Masuda Munetaka

机构信息

Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.

出版信息

Ann Thorac Cardiovasc Surg. 2017 Feb 20;23(1):19-25. doi: 10.5761/atcs.oa.16-00164. Epub 2016 Dec 27.

DOI:10.5761/atcs.oa.16-00164
PMID:28025447
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5347483/
Abstract

INTRODUCTION

The efficacy of platinum-based adjuvant chemotherapy (PBAC) for pathological stage II and stage III squamous cell carcinoma (SCC) of the lung was analyzed retrospectively.

MATERIALS AND METHODS

The prognoses of 94 patients with stage II and stage III SCC with or without PBAC (more than three courses of cisplatin-, carboplatin-, and nedaplatin-based adjuvant chemotherapy) were compared.

RESULTS

The mean observation period was 46.1 months. PBAC was not administered for the following reasons: 39 (55.7%) patients had comorbidities, 25 (35.7%) were older than 75 years, 19 (27.1%) patients underwent surgery before the approval of PBAC, and 3 (4.3%) patients could not continue PBAC (≤2 cycles) because of adverse events. PBAC patients (n = 24) were significantly younger than non-PBAC patients (n = 70; 66.3 vs 69.6 years old, respectively; p = 0.043). Disease-free survival (DFS) did not differ between PBAC and non-PBAC patients (55.0% and 67.1%, respectively; p = 0.266). PBAC patients tended to have worse overall survival (OS) than non-PBAC patients (56.1% and 70.2%, respectively; p = 0.138). PBAC was not prognostic for OS (hazard ratio (HR), 2.11; 95% confidence interval (CI), 0.82%-5.40%; p = 0.120).

CONCLUSION

PBAC did not improve the prognoses of patients with pathological stage II or stage III SCC in the single institution experience.

摘要

引言

回顾性分析铂类辅助化疗（PBAC）对肺病理Ⅱ期和Ⅲ期鳞状细胞癌（SCC）的疗效。

材料与方法

比较94例Ⅱ期和Ⅲ期SCC患者接受或未接受PBAC（超过三个疗程的顺铂、卡铂和奈达铂为基础的辅助化疗）的预后。

结果

平均观察期为46.1个月。未进行PBAC的原因如下：39例（55.7%）患者有合并症，25例（35.7%）年龄大于75岁，19例（27.1%）患者在PBAC获批前接受了手术，3例（4.3%）患者因不良事件无法继续PBAC（≤2个周期）。接受PBAC的患者（n = 24）明显比未接受PBAC的患者年轻（分别为66.3岁和69.6岁；p = 0.043）。PBAC组和非PBAC组患者的无病生存期（DFS）无差异（分别为55.0%和67.1%；p = 0.266）。接受PBAC的患者总生存期（OS）往往比未接受PBAC的患者差（分别为56.1%和70.2%；p = 0.138）。PBAC对OS无预后价值（风险比（HR）为2.11；95%置信区间（CI）为0.82%-5.40%；p = 0.120）。

结论

在单机构经验中，PBAC并未改善病理Ⅱ期或Ⅲ期SCC患者的预后。